Pioneering theranostics in immuno-oncology, PET radiotracer images T-cell & NK cell activation

A clinical-stage Australian biotech pioneering first-in-class radiopharmaceuticals for diagnostic and therapeutic use. They’re developing multiple theranostic agents targeting PD-L1, HER2, αvβ6 integrin, advanced prostate cancer, brain metastases, and more

Medison focuses on hazardous and healthcare waste and is cited as a key player in the medical waste market, including management of waste contaminated with radionuclides from diagnostic and radiotherapeutic procedures, making it relevant for theranos

National professional society for nuclear medicine in India for over 4 decades.

A global medical technology leader offering advanced imaging systems (like PET/CT and PET/MR), molecular diagnostics, and integrated healthcare solutions. They offer Theranostic imaging tools & integrate dosimetry software (Hermia) into their platforms.

Veolia provides international hazardous waste and nuclear services, including radioactive waste management and specialized services for healthcare. Their medical-waste divisions process regulated medical and pharmaceutical waste, and their nuclear /

Global provider of nuclear medicine & diagnostic imaging services operating radiopharmacies, PET & cyclotron services and theranostic offerings.

Offers comprehensive oncology drug development services, including models and assays instrumental in theranostic research—supporting both diagnostics and therapeutics through their deep oncology expertise and global infrastructure

A global contract research organization (CRO) based in Ireland. Also launched integrated theranostic services in Australia.

A full‑service Contract Research Organization (CRO) with offices in the U.S & Australia.

SHINE is a fusion-technology company that operates commercial facilities to produce medical isotopes, initially focusing on Mo-99/Tc-99m but expanding into therapeutic isotopes using accelerator-driven neutron sources.

A U.S.-based developer of precision quality control and calibration products for nuclear medicine, particularly SPECT and PET imaging, with worldwide distribution.

CANM is the leading organization for nuclear medicine professionals in Canada, offering education, advocacy, and support for the use of nuclear medicine and theranostics.

A Canadian CDMO that specializes in GMP manufacturing of radiopharmaceuticals—including isotopes like Lu-177, Ac-225, I-131, In-111, and Zr-89—enabling both diagnostic and therapeutic applications central to theranostic development.

Medidata is a leading provider of cloud-based SaaS and analytics platforms that support clinical research—from trial design and data capture to patient engagement, AI-powered insights, and decentralized trial technologies

Global nuclear medicine supplier with ~30 years in R&D, manufacturing and supply of radiopharmaceutical kits, and also a true CDMO

Triumvirate provides hazardous waste management with a heavy focus on healthcare, life sciences and hospitals. They offer radiation safety management, including consulting on radioactive waste reduction and recycling, and list radioactive materials a

Sanofi is a multi-therapeutic area pharmaceutical giant with a growing interest in radiopharmaceuticals and theranostics through a licensing agreement for lead‑212 radioligand therapy (AlphaMedix™) targeting neuroendocrine tumors

Plus Therapeutics is a U.S. clinical-stage pharmaceutical company developing innovative targeted radiotherapeutics, particularly nanoliposome-encapsulated Rhenium‑186 (Re‑186)

Kalitta Charters offers on-demand and scheduled air transport for radiopharmaceuticals, specializing in Next Flight Out services for theranostics shipments to ensure viability upon arrival at medical centers

A clinical-stage immuno-oncology imaging company that engineers “minibodies” (antibody fragments) for PET and optical imaging, enabling non-invasive visualization of immune cells (e.g. CD8 T‑cells) and tumor markers—a powerful theranostic tool for patient selection and treatment monitoring in cancer immunotherapy

A Swiss clinical‑stage biotech firm developing novel DARPin (Designed Ankyrin Repeat Protein) therapeutics for oncology. They’re advancing a Radio‑DARPin Therapy (RDT) platform—creating targeted radioligand treatments using DARPins to deliver radionuclide payloads

A leading global biopharmaceutical company developing medications and vaccines across oncology

A leading commercial supplier of Copper‑67 (Cu‑67), a high‑specific‑activity therapeutic isotope ideal for theranostic pairings when combined with diagnostic isotopes like Cu‑64 or Cu‑61—offering what’s called "perfect theranostic pairs" for precision imaging and therapy

US Ecology, now part of Republic Services, has long been active in low-level radioactive waste and hazardous waste management. They operate specialized treatment and disposal facilities handling radioactive waste, and market services for medical, res

A Tokyo-based biotech focused on peptide discovery (PDPS platform), developing peptide therapeutics and diagnostics—foundational to theranostic innovation.

International Centers for Precision Oncology (ICPO) Foundation is a non‑profit organization. It aims to advance Theranostics by scaling global patient access—through building a network of accredited clinical centers, standardized education & fostering a collaborative international community

ITM is a leading radiopharmaceutical biotech and isotope company, globally known for production and supply of therapeutic isotopes like n.c.a. Lu-177 and Ac-225, which are core to many theranostic agents

IBA is a technology provider that helps develop and operate PET radiopharmaceutical production centers, and is a key supplier in radiopharma and theranostic infrastructure

A UPS company excels in time-critical nuclear medicine transportation, offering white glove service for radiopharmaceuticals.

A digital health radiology platform that connects patients, healthcare providers, and pharmaceutical partners to a network of U.S.-based, subspecialty radiologists—offering rapid, expert second‑opinion imaging reads/RECIST (e.g. CT, PET)

MedChemExpress is a broad life-science reagent supplier that carries a sizeable catalog of bifunctional chelating agents such as DOTA, NOTA, HBED-CC derivatives, p-SCN-Bn-HOPO, DFO-DBCO and related constructs.

An Australian biotech developing dendrimer-based platforms for drug delivery and imaging agents, with potential theranostic applications, although it's primarily known for its antiviral and topical products.

IQVIA is a large global CRO / data & technology provider that reports having run more than 25 phase I–IV radiopharmaceutical clinical trials and supports RLT programs with its oncology and imaging infrastructure

Formed in 2021 as a sister company to Blue Earth Diagnostics—is focused on developing next‑generation targeted radiotherapeutics in oncology.

Siemens’ Radiopharma category combines PETNET Solutions (network of >40 radiopharmacies worldwide) and other assets, making it a global leader in PET radiopharmaceutical manufacturing and distribution.

A technology provider in the field of nuclear medicine, specializing in the design, manufacture, and support of advanced radiopharmacy equipment such as synthesizers, dispensers, and quality-control systems for radiopharmaceutical production.

Operates a large radiopharmaceutical manufacturing network and provides clinical supply, development, and manufacturing services, including for theranostic agents (e.g. FAPI, PSMA).

IRE is a public-utility foundation whose main activity is the production of radioisotopes for diagnostic and therapeutic nuclear medicine, and it is a global leader in fission Mo-99 for Tc-99m generators

A clinical‑stage radiopharmaceutical company pioneering image‑guided alpha-particle targeted therapies (Pb‑212) paired with matching imaging tracers (Pb‑203), forming a true theranostic platform to both visualize and treat cancer

Conference Organizer

Focused on developing a new class of targeted radiopharmaceuticals for solid tumors, putting theranostic principles—pairing diagnostic specificity with therapeutic payload—at the core of their strategy

A leading radiopharmaceutical company known for products that help clinicians “Find, Fight, Follow” diseases, primarily through diagnostic imaging—and is expanding into radiotherapeutics and theranostics solutions

CheMatech is a chelator specialist and SNMMI-facing player focused on the design and synthesis of macrocyclic chelating agents, especially DOTA, NOTA, NODAGA and related derivatives.

A commercial-stage biopharmaceutical company pioneering theranostic radiopharmaceuticals, developing both diagnostic and therapeutic agents for cancers and rare diseases—such as its FDA-approved PSMA‑PET imaging agent Illuccix®,CAIX for Renal Cell imaging and pipeline expansion into fibroblast activation protein (FAP) targeting for potential broad-spectrum theranostic utility

A German/U.S. MedTech that develops AI-driven software tools for enhanced prostate cancer management for personalized treatment prediction from PSMA PET

Swedish based, developer of vendor‑neutral molecular imaging and dosimetry software—most notably the Hermia platform—that supports PET/SPECT/CT/MR review, quantitative dosimetry (including voxel and organ dosimetry), and theranostics workflows 

NRG PALLAS operates the Petten nuclear infrastructure in the Netherlands, one of the most important reactors in the world for medical isotope production, providing Mo-99/Tc-99m and other isotopes used for millions of patient scans and treatments annu

JSC Isotope is a subsidiary of Rosatom and functions as the single industry operator that markets and exports isotope products produced across Rosatom enterprises, supplying over 70% of items in the global medical isotope product line and exporting t

GBI is a biologics CDMO with deep history in antibody conjugation, including radiolabeled antibodies used for imaging and therapy. Their own “Theranostic Manufacturing Solutions” materials highlight experience producing radiolabeled mAbs for cancer i

ANSTO is Australia’s national nuclear science organisation and operates the OPAL research reactor, producing the majority of the country’s radiopharmaceuticals, including Mo-99/Tc-99m, I-131 and Lu-177 for domestic and regional use>

Pioneering the manufacture and development of targeted alpha‑emitting radionuclide cancer therapies, aiming to bring advanced, high‑precision treatments to oncology patients globally

A subsidiary of Orano Med since 2011, specializes in macrocyclic chelating agents—highly engineered ligands that securely bind radioactive metals like lead‑212 for use in diagnostic imaging and Targeted Alpha Therapy (TAT) in oncology.

A global radiotherapeutics company with a comprehensive pipeline of radionuclide drug conjugates, such as the PSMA-targeted 225Ac‑FL‑020 and NTSR1-targeted 177Lu‑FL‑091, across Belgium, Germany, and China

A U.S.-based radiopharmaceutical CDMO offering services for both diagnostic and therapeutic radiopharmaceuticals—especially theranostic agents such as Gallium‑68 DOTATOC and novel radio‑ligand therapies. The company supports product development from research through commercialization

An Australian-based, global leader in automated PET radiochemistry instrumentation and radiopharmaceutical development, offering products like the MultiSyn, F‑18 FlexLab, and HPLC+ that power efficient tracer synthesis and quality control

Develops targeted alpha‑emitting radiotherapies, such as Actimab‑A (CD33-targeted using Ac‑225), and ATNM‑400, a prostate cancer-directed antibody radioconjugate—both deeply rooted in theranostics

Capintec is a core nuclear medicine and molecular imaging instrumentation brand, focused on dose calibrators, well chambers, shielding, and related radiation measuring devices from radiopharmaceutical prep to patient administration.

A global leader in diagnostic imaging . It plays a pivotal role in diagnostic imaging agents that enable theranostic approaches. Bracco acquired Blue Earth in 2019.

Avion is an Australian CRO with specialized imaging and radiopharma services, including management of radiopharmaceutical clinical trials, nuclear medicine imaging, and associated operational workflows.

Scientifically driven CRO & CDMO specialized in targeted radionuclide therapies, combining advanced oncology models and molecular imaging with development and manufacturing capabilities for radiopharmaceutical drug candidates. Strong fit for preclini

A global contract research organization (CRO) formed by merger of Clinipace & dMed. Provides clinical trial development support and services

A Chiliean pharmaceutical company (founded 2010) develops radiopharmaceuticals for molecular imaging—like 18F, NaF, 68Ga‑PSMA, and 68Ga‑DOTATATE—commonly used for PET scans in oncology

A global medical technology company specializing in molecular imaging, radiopharmaceuticals imaging tools, AI-driven dosimetry systems and through strategic ownership of other companies.

3P Biopharmaceuticals (now part of 3PBIOVIAN) is a biologics CDMO specializing in process development and cGMP manufacturing of recombinant proteins and mAbs.

A leader in clinical-stage radiopharmaceutical company pioneering Targeted Copper Theranostics (TCT) for both diagnostic imaging (64Cu) and therapeutic use (67Cu), powered by its proprietary SAR Technology platform

RDC is a long-running NVLAP-accredited dosimetry lab focused on personal radiation monitoring (badges, rings, fetal monitoring, etc.) for medical, dental, veterinary and other radiation-using practices.

An Israeli clinical-stage biotech pioneering Smart Targeted Radioligands (STRs) for precision oncology—theranostic compounds that both image and treat cancer by pairing disease-specific peptide targeting with therapeutic (alpha or beta) radiation delivery.

The most advanced and leading radiopharmaceutical clinical trials network based in U.S. Enabling any participating community cancers to rapidly launch & conduct first-in-world Molecular Imaging & Therapeutic Radiopharmaceutical trials with unmatched efficiency, quality and accruals

Ameriflight is a dedicated cargo airline with extensive experience in radiopharmaceutical transport, ensuring safe and punctual delivery of theranostics materials across the US and Puerto Rico via specialized charters

AZI is a US-based organization focused on nuclear medicine, with operations designed to produce medical isotopes from reactor-based sources for both research and clinical use. Their core mission is to secure reliable supplies of key radionuclides use

Sun Nuclear provides independent, integrated QA and dosimetry solutions used in more than 5,000 cancer centers worldwide, across RT and diagnostic imaging. Their QA platforms (e.g., SunCHECK) and dosimetry tools are used in centers implementing thera

A global, research-driven pharmaceutical company founded in 1941 and headquartered in Tokyo, Japan. It focuses on developing innovative prescription medicines, especially in oncology

Creative Peptides is a custom peptide manufacturer that explicitly markets chelator-containing peptides (e.g., DOTAGA / DOTA conjugates) for radiolabeling and molecular imaging, directly targeting the radiopharmaceutical and theranostic market.

A clinical-stage radiopharmaceutical biotech company engineering highly specific, peptide-based radiotherapies for cancer—exemplifying theranostics by combining tumor-targeted delivery with potent radionuclide payloads (e.g., Lu-177, Ac-225)

A leader in radiopharmaceuticals and nuclear medicine, offering a broad product portfolio supported by decades of experience and a presence in over 60 countries

A Canadian nuclear energy company that also generates medical isotopes (used in diagnostics and radioisotope therapies), making it a key upstream player in the theranostics ecosystem

A U.S.-based biotechnology company developing antibody-based theranostics, using its proprietary B-Body® bispecific (and now T-Body™ trispecific) platforms to engineer precision-targeted therapeutic antibodies for cancer

A leading global Contract Research Organization (CRO) that provides clinical research and regulatory consulting services to support biopharmaceutical and medical device companies in over 50 Countries

Develops precision-guided therapeutics, including biologics targeting challenging cancers; while not explicitly theranostic, their approach supports targeted therapeutic delivery

A global healthcare conglomerate active across pharmaceuticals, medical devices, and consumer health, with growing interest in radiopharmaceuticals and theranostics through various partnerships and research initiatives.

A global radiopharmaceutical company developing, manufacturing, and distributing diagnostic and therapeutic isotopes—particularly non-carrier-added Lu-177, Terbium-161, and Gallium-68 kits across Israel, Europe, and the U.S.

A China & U.S. based global CRO offering end-to-end clinical development services from Phase I to IV for pharmaceuticals, biologics, and medical devices

A global Contract Research Organization (CRO) based in the U.S, that provides comprehensive outsourced clinical development and data solutions across all drug development phases, serving pharmaceutical, biotechnology, and medical device clients.

Standard Imaging provides QA, absolute and patient dosimetry solutions for radiation therapy and diagnostic CT/CBCT, widely used in cancer centers implementing advanced RT and imaging.

A manufacturer of mobile and modular medical imaging units such as Mobile MRI, CT, PET/CT, and even transportable imaging trailers.

Life Couriers (formerly Associated Couriers) specializes in time-sensitive and compliant life science logistics across the U.S., including Theranostic agents, clinical trial materials, and precision medicine delivery.

Worldwide Clinical Trials is a global mid-size CRO with strong oncology capabilities and a specific focus on radiopharmaceutical development, including dedicated scientific leadership and materials on radiopharmaceutical drug development strategy

A U.S.-based expert in nuclear medicine logistics, MDS provides safe, compliant door-to-door transport of radiopharmaceuticals nationwide, serving nuclear pharmacies and diagnostic/therapeutic radiopharma shipping clients.

A Swiss clinical-stage biotech company pioneering copper-based radiotheranostics, using Copper-61 for PET diagnostics and Copper-67 for targeted radiotherapy via its proprietary CuTrace™ platform, aiming to provide scalable, precise theranostic solutions across various cancers.

A U.S. based, oncology-focused CRO that helps advance cancer therapies from preclinical stages through clinical trials to FDA approval, offering trial design, data management, flow cytometry, and medical/regulatory support

Developing targeted alpha therapies using Lead-212 (²¹²Pb), aimed at selectively destroying cancer cells with minimal impact on healthy tissue, and has an active industrial production platform.

A Saudi Arabian radiopharmaceutical manufacturer that specializes in producing and supplying diagnostic and therapeutic radiopharmaceuticals, including cyclotron operation, radionuclide therapy, and radiopharmacy services

RayzeBio, based in San Diego, focuses on precision radiopharmaceutical therapies using actinium-225 (Ac‑225), an alpha-emitting isotope, positioning itself as a leader in the next wave of cancer theranostics.

Eckert & Ziegler is a Berlin-based global provider of isotope technology with business segments dedicated to medical, research and industrial applications. In nuclear medicine they produce a broad range of radionuclides and sources

SRS is an international body that promotes the development and application of RLTs in medical imaging and theranostics. It holds conferences and offers education and networking opportunities for professionals in nuclear medicine and theranostics

A Healthtech software and services company based in Wisconsin. They specialize in patient‑specific radiopharmaceutical therapy (RPT) dosimetry, offering advanced AI‑driven software and professional dosimetry services for both clinical settings and cl

develops vendor‑neutral medical imaging software used across radiation oncology, radiology, nuclear and molecular medicine, interventional radiology, and neuro/cardiac imaging—helping streamline complex clinical workflows

A U.S./Swiss preclinical-stage biotech developing the YB‑800 theranostics platform, including radiopharmaceuticals and diagnostics targeting novel tumor markers

Main professional society for nuclear medicine in Australia and New Zealand. ANZSNM has a strong focus on training, accreditation across ANZ, heavily cited in global discussions about workforce & training in theranostics.

A Denmark‑based scientific Contract Research Organization (CRO) and Contract Development & Manufacturing Organization (CDMO) specializing in targeted radionuclide therapies, molecular imaging services, and translational research

ADCO is one of the older U.S. low-level radioactive waste brokers/transporters, operating since 1965. They specialize in transportation and disposal of radioactive waste with services marketed to laboratories & hospitals, which aligns well with nucle

JPT is a peptide specialist with strong activity in custom peptide libraries and GMP-grade peptides, including radiopharmaceutical and theranostic precursors such as PSMA-11 and other targeting peptides used in nuclear medicine trials. Their peptides

Eckert & Ziegler is one of the major global isotope technology companies, with a Radiopharma division that offers contract manufacturing and development of radiopharmaceutical APIs and finished products.

A Swedish based global CRO that combines comprehensive clinical development services with flexible resourcing and Functional Service Provider solutions in Oncology and operates in more than 40 countries.

A precision oncology company leveraging next-generation antibody conjugation technologies & TRT to develop targeted cancer therapies

Bachem is one of the largest global peptide CDMOs and explicitly markets its expertise in peptides for molecular imaging and radiopharmaceuticals, including precursors used in peptide receptor radionuclide therapy (PRRT) and diagnostic tracers.

WARMTH is a worldwide nonprofit dedicated specifically to radionuclide molecular therapy and the “theragnostics/theranostics” paradigm, bringing together professionals focused on therapeutic nuclear medicine.

Thermo Fisher’s radiation detection & measurement division provides survey meters, contamination monitors, area monitors and passive dosimetry. Their instruments support radiation protection, environmental monitoring and dose tracking for facilities.

A clinical-stage oncology company pioneering targeted alpha therapeutics, using their proprietary Fast‑Clear™ linker technology to deliver alpha-emitting isotopes to tumors with improved safety and precision. In 2024 acquired by Astra Zeneca

A French CDMO offers turnkey technologies and supply chain solutions for the production and distribution of key theranostic radionuclides—including non-carrier-added Lutetium-177, Actinium-225, and Terbium-161

Mirion is a global provider of radiation detection and dosimetry solutions. Mirion Medical (Capintec, Sun Nuclear, Biodex) supplies dose calibrators, QA devices, and radiation monitors specifically for nuclear medicine and molecular imaging.

Australia's first publicly funded cancer center soley dedicated to cancer treatment, research and education.

CPDC is one of the original radiopharmaceutical CDMOs, focused on PET/SPECT and therapeutic agents, including n.c.a. Lu-177 supply and GMP manufacturing of radiopharmaceuticals.

Ratio Therapeutics (Boston) develops next‑generation small-molecule radiopharmaceuticals designed for theranostic use—able to accommodate both imaging and therapeutic radioisotopes—leveraging its Trillium™ targeting scaffold for precision oncology

ABX (Germany) manufactures and supports radiochemistry reagents, PET isotopes—such as precursors for nuclear medicine and radiopharmaceutical research—thus providing critical components for theranostic drug development

CPC Scientific is a global peptide & oligonucleotide CRDMO with extensive custom peptide capabilities, including peptides used in dually radiolabeled constructs for nuclear medicine and theranostic research

A innovative biotech incubator and umbrella company founded in 2018, specializing in next-generation radioligand therapies—particularly using Terbium-161—for prostate cancer and other tumor types as part of its theranostics portfolio

PPD, the clinical research business of Thermo Fisher, runs global radiopharmaceutical therapy trials and actively markets “extensive experience supporting complex radiopharmaceutical trials” and best practices for RLT studies.

A specialized conference series dedicated to advancing the development & clinical translation of targeted radiopharmaceuticals. With a strong focus on isotope supply chains, regulatory challenges, and innovative molecular design

Crown Bioscience is a preclinical oncology & immuno-oncology CRO whose platforms are used extensively for radiopharmaceutical and theranostic agent evaluation. They’ve partnered with Molecular Imaging / MDC

A global contract research organization (CRO) based in the U.S. Provides oncology clinical trial services

EANM is the main nuclear medicine society in Europe and explicitly includes Oncology & Theranostics among its core committees. Its education arm, ESMIT, runs structured courses, webinars and e-learning, including content on radioligand therapy, dosim

Y‑mAbs is a commercial-stage biopharmaceutical company developing and commercializing novel radioimmunotherapies, centered around its Self‑Assembly DisAssembly Pre‑targeted Radioimmunotherapy (SADA‑PRIT) platform.

A global pharmaceutical leader that actively develops and commercializes radioligand therapies, exemplified by its acquisition Endocyte (Pluvicto®) and of Mariana Oncology to strengthen its theranostics pipeline

SNMMI is one of the main global professional societies in nuclear medicine and molecular imaging, with a growing focus on radiopharmaceutical therapy and theranostics. They are also involved in radiopharmaceutical therapy accreditation.

Engineers precision radiotherapeutics via its proprietary ROVEr™ platform, crafting antibody‑based agents with tunable pharmacokinetics to maximize tumor targeting while minimizing systemic toxicity—a strong theranostic approach

Clym is a healthcare-focused environmental services firm that provides radioactive, medical, mixed, and hazardous waste disposal plus decommissioning and safety services to hospitals, research labs, and life-science facilities.

A Canadian specialized CDMO and leading developer of medical isotopes and radiopharmaceutical products—including Actinium-225, Lutetium-177, and Technetium-99m generators

A global pharmaceutical leader with extensive oncology and precision medicine pipelines and more recently involved with the development of Theranostic agents

A Belgian joint venture between IBA and SCK CEN focused on large-scale production of Actinium-225, a key alpha-emitting radioisotope used in theranostics for targeted cancer therapies—and has entered strategic agreements to supply Ac-225, such as with Bayer

A full‑service Contract Research Organization (CRO) with services in 40+ Countries

AFNMB is the main organization serving the nuclear medicine community across the Asia-Oceania region. AFNMB supports educational programs & conferences focused on theranostics.

POLATOM, part of the National Centre for Nuclear Research (NCBJ), is a manufacturer and distributor of medical and industrial radioisotope products, including Mo-99/Tc-99m generators, diagnostic kits, and multiple therapeutic radionuclides. Its produ

Eichrom supplies radiochemistry reagents and ion exchange resins extensively used in nuclear medicine and radiopharmaceutical research—crucial for theranostic development.

A molecular imaging company (a subsidiary of Bracco Imaging) that develops precision PET radiopharmaceuticals for cancer diagnostics, with a focus on agents like Axumin® and POSLUMA® for prostate cancer imaging using radiohybrid technology.

Global CDMO specialized in diagnostic and therapeutic radiopharmaceuticals with development, manufacturing and radiopharmacy networks across North America and Europe; actively expanding into radiotherapeutic production.

Actithera has developed a platform that maximizes radiation dose to tumor through covalent bonding. It is isotope agnostic.

Ariceum Therapeutics GmbH develops next-generation targeted radiopharmaceuticals to visualize and treat cancer, clearly aligning with theranostic approaches

A venture capital and private equity firm that partners with founders to build and scale transformative companies across physical industries—ranging from manufacturing and energy to healthcare infrastructure, robotics, and supply chain systems .Eclipse co-created Nucleus RadioPharma, a CDMO centered on radiopharmaceutical development

Focuses on a Necrosis Targeting Platform Technology (NTPT) for cancer imaging and targeted radiotherapy—key theranostic components aiming to both detect and treat tumors

North America’s leading provider of waste collection, disposal, and recycling services, including hazardous waste management

IBA Dosimetry provides dosimetry systems for radiation therapy, particle therapy and medical imaging, including tools used in SPECT/PET environments and hybrid theranostic workflows. Their platforms & detectors are used to validate dose delivery and

An Austrian-based CDMO and analytical-services provider specializing in radiopharmaceutical development, production, and quality control—including the manufacture of therapeutic isotopes such as Lu‑177, Ac‑225, and F‑18

Ludlum designs and manufactures a broad range of radiation detection instruments, including survey meters, area monitors and specialized detectors used in nuclear medicine departments, hot labs, and radiopharmacy environments

Marken provides precision logistics for radiopharmaceuticals, accelerating delivery of theranostics therapies through a global network that handles radioisotope shipments with expertise in customs and regulatory compliance.

A Japanese company specializing in nuclear medicine imaging agents, actively involved in peptide-based theranostics and commercial-scale production of actinium‑225 for alpha therapies

Perma-Fix is a nuclear services company and a leading provider of radioactive and mixed waste management, specifically stating it manages radioactive and mixed waste for hospitals, research labs and institutions

The Theranostics World Congress is a dedicated global congress focused entirely on theranostics.

Professional SocietyA non-profit scientific & professional organization that promotes the advancement of Nuclear Medicine, Molecular Imaging & Theranostics through education & research

A non‑profit, public‑benefit organization dedicated to advancing theranostics for cancer care on a global scales through aising awareness, educating patients and healthcare professionals, supporting research and development, and improving access to these targeted treatments worldwide

A U.S. based Network of private practice centers specializing in Theranostics

A U.S.-based manufacturer of radioactive materials—including the only FDA-approved Sodium Iodide I‑131 drug product produced domestically—alongside calibration standards, cobalt-60 sealed sources, and isotope APIs for third-party theranostics developers

RSNA is a major medical society focused on radiology and related fields, including nuclear medicine and molecular imaging. RSNA hosts the world’s largest annual radiology conference, including content on theranostics.

Pan-European molecular imaging society covering basic, translational and clinical imaging science, including image-guided therapies and theranostics. Annual EMIM Conference involved Theranostic concepts

PolyPeptide Group is a focused global CDMO for peptide- and oligonucleotide-based APIs, and offers tailored solutions for radiolabeled peptides as part of its peptide CDMO portfolio.

A global pharma and life sciences company with a broad drug development portfolio in oncology with Radium 223 and including a growing pipeline of Theranostic Agents

Pharma (Japanese)

Orano TN specializes in nuclear materials transport, including casks and logistics for radiopharmaceutical precursors used in theranostics, with over 50 years of risk management expertise.

Bio X Cell is a specialist manufacturer of in vivo-grade monoclonal antibodies widely used as tools in immuno-oncology, imaging and experimental theranostics. Their antibodies include PSMA-targeted and checkpoint-targeted clones

ORTEC is a global manufacturer of radiation detectors and nuclear instrumentation used in labs, nuclear facilities medical / research centers. In theranostics, ORTEC’s spectrometry and detector systems are utilized in research/radioisotope production

A clinical-stage biotech firm developing a novel class of alpha radioligand therapies (ARTs)—a clear theranostic modality—using Pb‑212 and their proprietary AlphaDirect™ technology to enable targeted delivery with high efficacy and safety

Tigermed is a large China-origin global CRO that markets radiopharmaceutical development capabilities, including support from preclinical through phase I–IV, with services covering medical imaging, regulatory, data management and more.

A clinical-stage biotech company developing next-generation targeted radiotherapies—notably radioantibody platforms that harness alpha-particle radiation for precision cancer treatment

SK Biopharmaceuticals a global biotech based in South Korea and is active in radiopharmaceutical therapy, partnerships with KIRAMS for actinium-225 RPT and with Full-Life for the FL-091 radioligand.

an Irish global CDMO delivering end-to-end pharmaceutical services—from drug discovery, development, and API production to clinical trial support and diagnostics—including biomarker-driven precision medicine solutions, which are pivotal to theranostic strategies

An oncology CRO specializing in preclinical and clinical testing—including radiopharmaceutical testing and patient-derived tumor models—supporting theranostic drug development through real-world validation platforms

RPO Group explicitly brands itself as a radiotheranostic CRO, focused on early-phase clinical development of radiotheranostic agents.

A global leader in cyclotron technology & radiopharmaceutical manufacturing, supplying equipment

PCF is the world’s leading philanthropic organization dedicated to funding life-saving prostate cancer research. It has been a major driver of PSMA biology, imaging, and treatment research, and its scientific programs for prostate cancer.

A France-based software company specializing in personalized voxel-based dosimetry tools for radiation oncology and nuclear medicine, including the PLANET® platform that supports multi-radionuclide dosimetry across diagnostic and therapeutic workflows

NTP Radioisotopes SOC Ltd, a subsidiary of the South African Nuclear Energy Corporation (Necsa), is one of the world’s leading producers of medical radioisotopes, supplying a significant share of global molybdenum-99 (for Tc-99m generators) as well a

A global contract research organization (CRO) and functional service provider offering clinical development, resourcing, and quality services across multiple therapeutic areas, including oncology and diagnostics

Manufactures injectable radiopharmaceutical “cold kits” (e.g. Tc-99m kits) and other sterile parenterals, and operates as a contract manufacturer for radiopharmaceutical injectables within Sun’s broader sterile injectables CDMO offering.

A pioneering developer of high-definition, solid-state digital SPECT and SPECT/CT imaging systems—such as the ring-shaped VERITON-CT—that support theranostics applications by enabling precise imaging, dosimetry calculation, and treatment response

A full-service U.S.-based biopharmaceutical CDMO. Expertise in bioconjugation includes direct conjugation of Ac‑225 to monoclonal antibodies. They’ve also worked with other isotopes for theranostic applications, including Lu177, Zr‑89, In‑111, Bi‑213, Pb‑212

UPS Healthcare delivers end-to-end logistics and supply chain solutions tailored to pharmaceuticals, diagnostics, clinical trial logistics, and medical device delivery, making it suitable for theranostics and other sensitive healthcare shipments

A clinical-stage biotechnology company based in Houston, developing targeted radiopharmaceuticals and emphasizing a theranostic approach for cancer—supporting diagnosis, monitoring, and therapy with both alpha- and beta-labeled agents.

A global radiopharmaceutical CDMO based in Istanbul, supplying GMP-grade radioisotopes and theranostic radiopharmaceuticals—particularly high-specific-activity agents like Lutetium-177—across a robust logistics network serving over 70 countries.

A family-owned provider of medical imaging and therapeutic technologies, offering sales, service, consulting, education, and project management across modalities such as MRI, CT, ultrasound, nuclear/molecular imaging, and surgical systems

Syneos Health is an integrated biopharma solutions organization that includes a large oncology CRO unit with explicit experience in radiopharmaceutical studies.

Isotopia is a radiopharmaceutical company with significant CMO/CDMO-like services, specializing in isotopes and finished radiopharms, including Lu-177 and other therapeutic isotopes.

Landauer specializes in radiation safety, offering dosimetry services, medical physics consulting, and radiation monitoring tools—technologies essential for safe handling of theranostic radiopharmaceuticals

FedEx Custom Critical®, a Nuclear Medicine shipping service, which is specifically designed for the transport of short-lived radiopharmaceuticals used in PET, SPECT, and therapeutic applications. This service provides time-definite delivery, chain-of-custody security, and regulatory compliance for radioactive medical shipments

AirNet II provides 24/7 specialized air cargo for radiopharmaceuticals, focusing on compliant and secure transport of theranostics agents with direct routing to avoid sorting facilities.

Polimaster provides radiation detection equipment such as personal dosimeters, PRDs, portal monitors and handheld detectors. Hospitals and medical waste facilities use these devices for radiation control, access control and waste stream monitoring.

A clinical biopharmaceutical company developing targeted radiotherapeutic agents using its proprietary Phospholipid Drug Conjugate (PDC™) platform, notably iopofosine (CLR‑131) and novel radioactive payloads for theranostic cancer treatments.

WMIS focuses on advancing molecular imaging and theranostics globally. Through its educational programs, scientific meetings, and publications, it serves as a platform for professionals involved in nuclear medicine, radiopharmaceuticals, and theranos

A biotech company developing personalized radiopharmaceuticals designed to diagnose and treat aggressive cancers, with a focus on precision theranostic modalities

PTW is a long-standing global market leader in high-precision dosimetry and quality control solutions for radiation medicine, including RT and diagnostic imaging. Their ion chambers, phantoms, and QA systems.

A Novartis subsidiary, is developing next-generation precision radioligand therapies to deliver targeted radiation treatments with minimized impact on healthy tissue including the target B7H3.

A clinical-stage Belgian biotech developing precision radiopharmaceuticals using camelid single-domain antibodies. Their platform enables theranostic pairing—first imaging, then therapeutic dosing using the same targeting molecule

A clinical-stage radioligand therapy company developing next-gen radioligand treatments for cancer. It was acquired by Eli Lilly in October 2023 to bolster their oncology portfolio.

Clean Harbors is one of the largest hazardous waste firms in North America. This includes programs that manage regulated medical waste “including radioactive” streams for hospitals and labs, which is directly relevant to PET/SPECT and theranostic rad

A healthcare investment firm (founded in 2015) that provides growth capital and strategic support to companies across the healthcare and life sciences sectors—including therapeutics, diagnostics, and related innovations

An early-stage radiopharmaceutical company developing novel oncology agents for solid tumors.

A major pharmaceutical company headquartered in Indianapolis, expanding into radiopharmaceuticals and theranostics notably through the $1.4 billion acquisition of Point Biopharma, which bolsters its radioligand therapy capabilities

Trinity Medical Solutions, a Strata Critical company, provides time-critical medical logistics for radiopharmaceutical, including rapid air and ground transport between manufacturing sites, hospitals, and imaging/therapy centers. Their infrastructure

ALAMN serves as the representative body for nuclear medicine professionals in Latin America. The association focuses on the promotion of nuclear medicine and theranostics, supporting research and education in the application of radiopharmaceuticals

Developing differentiated radiopharmaceutical therapies (RPTs) and companion diagnostics for hard-to-treat cancers, advancing theranostic agents such as ART‑101 (a PSMA-targeting radiotherapeutic) and a theranostic pair ARC‑706/ARC‑166

EMS is a national hazardous-waste company that specifically lists radioactive waste solutions, including materials like F-18 and Tc-99m from medical and pharmaceutical environments, and supports labs, hospitals, and healthcare facilities.

TheraSphere Y90

Chelatec is a preclinical CRO specialized in radiolabeling, ADME/PK and radiopharmaceutical non-clinical studies. They support radiopharmaceutical and theranostic development by providing custom radiolabeling

RaySafe focuses on X-ray radiation dosimetry and dose management, providing personal and area dosimeters, survey meters and integrated dose management tools. In theranostic centers, RaySafe equipment is part of the radiation protection ecosystem.

Monrol is a nuclear medicine company that operates as both a CMO and CDMO for radiopharmaceuticals, including extensive n.c.a. Lu-177 production. They provide early development support, fully integrated manufacturing services, and distribution

An immuno-oncology company developing radiotherapeutic and imaging agents targeting Glypican‑1 (GPC‑1) for solid tumors, with its lead candidate, Miltuximab®

A U.S.-based cyclotron and radiopharmaceutical technology company that provides compact cyclotron solutions and end-to-end manufacturing of diagnostics like therapeutic alpha radionuclides (Astatine-211, Actinium-225)

ABX-CRO is a specialized radiopharmaceutical and oncology CRO based in Dresden, providing full-service support across preclinical and clinical development for radiolabeled drugs.

Grupo RPH, also referred to as R2Pharma is a Brazilian radiopharmaceutical CDMO specializing in the production of cold kits and radiopharmacy solutions for diagnostic imaging. They operate the only privately owned GMP nuclear medicine manufacturing f

A Norwegian CDMO, established in 2023 as a spin-off from the Institute for Energy Technology and partially owned by Pharmalogic, that specializes in the development, commercial-scale production, and global distribution of radiopharmaceutical therapies.

TCI is a large global lab-chemical manufacturer, but they are specifically referenced in theranostic literature and their own topics materials as a supplier of chelating scaffolds and building blocks, including NODAGA and other chelators relevant to

The ACR is a major professional organization that represents radiologists and related specialists, including those in the nuclear medicine and molecular imaging fields. It offers continuing education, training, and accreditation services related to t

Berthold develops instruments for biosciences, industrial process control and radiation protection, including dose-rate meters and monitoring systems for radioactive contamination and airborne activity.

MTTI is a that develops radiolabeled compounds that can be used in bother PET/SPECT imaging and Radionuclide therapy. It develops PSMA targeted ligands and their pipeline includes small molecules and antibody based radiopharmaceuticals.

Cardinal Health’s Nuclear & Precision Health Solutions group runs one of the largest radiopharmacy networks and offers radiopharmaceutical contract manufacturing and dose preparation services. They manufacture and distribute PET/SPECT agents

SpectronRx is a radiopharmaceutical CDMO and radiopharmacy network that develops, manufactures, and distributes diagnostic and therapeutic radiopharms.

A global, technology-enabled clinical research services provider formed from the merger of Calyx and Invicro. They deliver imaging biomarkers, eClinical solutions, clinical adjudication, and imaging core lab services with expertise in oncology

Biosynth is a global supplier of peptides and key biologics, with a dedicated theranostics services offering for radiopharmaceuticals. They highlight synthesis of radiolabeled peptide precursors and “smart peptide technologies”

A clinical-stage oncology company developing novel targeted cancer therapies across platforms such as immunotherapies, radioligand therapies, and antibody-drug conjugates, using proprietary memory B cell hybridoma technology to uncover underexplored targets